Breztri Asthma Trials

What are the pivotal BREZTRI asthma trials?

KALOS and LOGOS Phase III trials.

What type of trials were KALOS and LOGOS?

Randomized, double-blind, double-dummy, multicenter Phase III trials.

Who was studied in the KALOS and LOGOS trials?

Patients with uncontrolled asthma (≥12 years old).

What is BREZTRI?

Triple therapy: ICS/LAMA/LABA (budesonide/glycopyrrolate/formoterol).

What was BREZTRI compared against?

Dual therapy ICS/LABA.

What were the primary endpoints of the BREZTRI trials?

Lung function improvements (FEV1 AUC0-3 and trough FEV1).

What was the trough FEV1 improvement in the BREZTRI trials?

+76 mL vs ICS/LABA (p<0.001).

What was the FEV1 AUC0-3 improvement in the BREZTRI trials?

+90 mL vs ICS/LABA (p<0.001).

What happened to exacerbations in the BREZTRI trials?

Reduced annualized severe exacerbations.

Was the benefit of BREZTRI limited to frequent exacerbators?

No, benefit seen regardless of recent exacerbation history.

How fast did BREZTRI work?

Improved lung function within 5 minutes.

Any new safety signals related to BREZTRI?

No new safety or tolerability findings.

What is the main takeaway from the BREZTRI studies?

Better airflow and fewer exacerbations vs dual therapy.

Why does triple therapy (BREZTRI) work better?

Adds LAMA bronchodilation to ICS/LABA.

Is BREZTRI a rescue inhaler?

No, maintenance therapy only.

Who is BREZTRI approved for?

Asthma patients ≥12 years.

What is a simple explanation for BREZTRI's benefit?

“Triple therapy improves breathing and helps prevent attacks.”

What is the best stat to remember about BREZTRI?

+76 mL trough FEV1.

What is another key stat about BREZTRI?

+90 mL AUC0-3.

What should a clinician say to a patient already on ICS/LABA?

Trials show BREZTRI outperformed ICS/LABA.

What should a clinician say if a patient has no recent exacerbations?

Benefit still observed with BREZTRI.

Why does the convenience of a single inhaler matter?

Simplifies regimen and may improve adherence.